

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713617200>

Synthesis of Differently Protected 1-C-Methyl-Ribofuranoses Intermediates for the Preparation of Biologically Active 1'-C-Methyl-Ribonucleosides

Laura Alessandrini^a; Silvana Casati^a; Pierangela Ciuffreda^a; Roberta Ottria^a; Enzo Santaniello^b

^a Dipartimento di Scienze Precliniche LITA Vialba, Università degli Studi di Milano - Via G. B. Grassi, Milano, Italy ^b Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli Studi di Milano - Via A. di Rudinì, Milano, Italy

To cite this Article Alessandrini, Laura , Casati, Silvana , Ciuffreda, Pierangela , Ottria, Roberta and Santaniello, Enzo(2008) 'Synthesis of Differently Protected 1-C-Methyl-Ribofuranoses Intermediates for the Preparation of Biologically Active 1'-C-Methyl-Ribonucleosides', *Journal of Carbohydrate Chemistry*, 27: 5, 332 – 344

To link to this Article: DOI: 10.1080/07328300802217848

URL: <http://dx.doi.org/10.1080/07328300802217848>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Synthesis of Differently Protected 1-C-Methyl-Ribofuranoses Intermediates for the Preparation of Biologically Active 1'-C-Methyl-Ribonucleosides

Laura Alessandrini,¹ Silvana Casati,¹ Pierangela Ciuffreda,¹ Roberta Ottria,¹ and Enzo Santaniello²

¹Dipartimento di Scienze Precliniche LITA Vialba, Università degli Studi di Milano – Via G. B. Grassi, Milano, Italy

²Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli Studi di Milano – Via A. di Rudini, Milano, Italy

Starting from D-ribose, differently protected 1-C-methyl-D-ribofuranoses have been prepared as intermediates for the synthesis of variously modified 1'-C-methyl-ribonucleosides, a class of compounds potentially endowed with interesting biological activity.

Keywords 1-C-Methyl-D-ribofuranoses, 1-Deoxy-psicofuranoses, D-Ribonolactone, Tetrapropylammonium perruthenate

INTRODUCTION

Synthetic nucleosides with modifications in the carbohydrate or base moiety are often characterized by anticancer^[1] or antiviral^[2–4] activity. In this respect, 40 years ago it was recognized that modifications at the 1'-position of adenosine, as in psicoadenosine (Fig. 1), “prevent deamination, while

Received April 22, 2008; accepted May 20, 2008.

Address correspondence to Pierangela Ciuffreda, Dipartimento di Scienze Precliniche LITA Vialba, Università degli Studi di Milano – Via G. B. Grassi, 74-20157 Milano, Italy. E-mail: pierangela.ciuffreda@unimi.it




Figure 1: Structure of 1'-C-substituted nucleosides, 1-deoxy-psicofuranose derivatives, and D-ribonolactone.

permitting good growth inhibitory activity.”^[5] Therefore, “modifications at this position, although chemically difficult, appear to be desirable.”^[5]

Due to this synthetic difficulty, only a few 1'-C-substituted nucleosides have been prepared so far^[6–9] and new promising biological activity for this class of compounds has been recently disclosed.^[10] For our project related to the synthesis of analogues of 1'-C-methyl-adenosine,^[11,12] gram quantities of 1-deoxy-psicofuranoses were required (Fig. 1).


RESULTS AND DISCUSSION

Synthesis of Differently Protected D-Ribonolactone Derivatives from D-Ribose

D-Ribonolactone would represent the ideal starting material for this synthesis, but its high price is not adequate to large-scale preparations. For this reason, D-ribose has been chosen as the alternative starting material as already proposed for the preparation of kilogram scale of a few D-ribonolactone derivatives.^[13,14]

We have tried classical oxidations including the reactions with permanganate^[13] or pyridinium chlorochromate^[15] and the reagent of choice was tetrapropylammonium perruthenate (TPAP) under catalytic conditions with N-methylmorpholine N-oxide (NMMO) as co-oxidant.^[16] This oxidizing system, previously applied to the synthesis of lactones from pyranoses and furanoses protected as benzyl and allyl ethers,^[17] allowed a nearly quantitative transformation (95% of recovered purified product) of protected D-ribofuranoses **2**, **3b**, and **4** to the corresponding lactones **5**, **6**, and **7** (Sch. 1).

The preparation of lactone **6** started from the reaction of D-ribose (**1a**) with benzaldehyde in the presence of zinc chloride.^[18] 2,3-Benzylidene derivative **3a** was obtained as an *endo/exo* mixture of the phenyl group of the benzylidene moiety, the β -anomer prevailing over the α -one (8:1 ratio).^[19] ¹H NMR



Scheme 1: Synthesis of protected D-ribofuranose derivatives **5**, **6**, and **7**.

analysis of the two products purified by flash chromatography showed that the less polar product corresponds to the β -anomer, characterized by signals of H-C(1) (doublets at 5.53 and 5.56 ppm) coupled with H-C(2) ($J < 1$ Hz). The more polar product corresponds to the α -anomer, characterized by signals of H-C(1) (doublets at 5.96 and 5.98 ppm) coupled with H-C(2) ($J = 3.7$ Hz). Compound **3a** was utilized as a crude α/β mixture, silylated to ribofuranose **3b**, which was then oxidized with TPAP/NMMO to lactone **6** (3:1 *exo/endo*, overall yield from D-ribose 51%). The *endo* (or *R*) configuration for the phenyl group of the major isomer of compound **6** was assigned by analysis of the NOE experiment. Saturation of the benzylidene proton resulted in NOEs of H-C(2) and H-C(3) signals, whereas H-C(4) was not affected. As a complementary result, in the minor isomer the irradiation of the benzylidene proton led to H-C(4) signal enhancement and the configuration *exo* (or *S*) was assigned.

We have also synthesized 2,3,5-tribenzyl-D-ribo-1,4-lactone **7**, considering that the corresponding 1-*C*-methyl-ribofuranose **10** could be a useful intermediate for the synthesis of 1'-*C*-methyl-adenosine. 2,3,5-Tri-*O*-benzyl-D-ribofuranose (**4**) was prepared from 1-*O*-methyl-ribofuranose (**1b**) essentially as described in the literature^[20] and quantitatively oxidized to lactone **7** using TPAP/NMMO (Sch. 1).

Synthesis of 1-*C*-methyl-ribofuranoses


Reaction of protected D-ribofuranose derivatives with organometallic reagents is a well-known methodology for the synthesis of *C*-nucleosides.^[21] It has been reported that ribofuranose **5** reacts with methyllithium at low temperature to

afford the corresponding 1-deoxy-psicofuranose **8**, as only one anomer.^[6,7,11] Opening of the ribonolactone to the corresponding methyl ketone and related formation of a tertiary alcohol reported for other lactones^[22] were not observed in the case of lactone **5**.^[23] We have verified that **8** presents only the α -OH and have not observed the formation of other competing side products. Under the same conditions, the methylation of 2,3-benzylidene lactone **6**^[11] afforded a mixture of unidentified products along with 1-deoxy-psicofuranose **9** that could only be isolated in 38% yield. Compound **9** is an *endo/exo* mixture of the anomer that presents the methyl group in the α position, as evidenced by NOE experiments in which irradiation of methyl group at C-1 led to H-C(5) enhancement. In the ¹H NMR spectrum of compound **9** we observed two signals corresponding to the 1-methyl at 1.62 ppm (*exo*) and 2.38 ppm (*endo*). The downshift of the signal at 2.38 ppm in the *endo*-**9** can be explained by the influence of the vicinal phenyl group at the same side of the methyl group.


Finally, we examined the methylation of lactone **7** and obtained compound **10** in good yield (91% of purified product) as an anomeric mixture (1 α -CH₃:3.5 β -CH₃ ratio, as determined by NMR analysis) with no evidence for other side products (Sch. 2).

Acetylation of 1-C-methyl-ribofuranoses

The synthesis of 1'-C-methyl-nucleosides required the acetylation of 1-deoxy-psicofuranoses before the coupling with the base.^[6,7,9,11] The



Scheme 2: Methylation of lactones **5**, **6**, and **7**.



Scheme 3: Acetylation of 1-C-methyl-ribofuranoses **8**, **9**, and **10**.

acetylation of compound **8** has been studied in detail and it has been demonstrated that, starting from an anomerically pure **8**, an α/β mixture of acetate **11** is formed (α -anomer 28%, β -anomer 58%).^[11]

The acetylation of anomerically pure **9** yielded an equimolar mixture of four acetyl derivatives **12**, α -acetate (*endo/exo*), and β -acetate (*endo/exo*) with a small amount of acyclic compounds, and this discourages from the use of this intermediate for 1'-C-methyl-nucleosides synthesis. Under the same conditions of acetylation, 1-deoxy-psiicofuranose **10** afforded only one product (60% yield) that did not correspond to the expected cyclic acetate **14**. ^1H NMR analysis of the isolated product showed resonances of H-C(5) at 5.32 ppm and of H-C(3) at 4.05 ppm, consistent with an acyclic structure. The singlet at 2.14 ppm in the ^1H NMR spectrum and the signal at 208.19 in the ^{13}C NMR spectrum suggested that a methyl ketone was present in the structure. Furthermore, the resonance at 169.76 ppm in the ^{13}C NMR indicated the presence of an acetate and the structure of acyclic ketoacetate was proposed for the product **13** (Sch. 3).

CONCLUSIONS

We have investigated the preparation of a few 1-C-methyl-ribofuranoses starting from D-ribose (**1a**), which was transformed in the corresponding

derivatives **2**, **3b**, and **4**. The oxidation of these compounds to the corresponding lactones **5**, **6**, and **7** has been quantitatively achieved with TPAP under catalytic conditions with NMMO as co-oxidant. The methylation of lactones **5** and **7** satisfactorily afforded 1-C-methyl-ribofuranoses **8** and **10**, whereas the yield of 1-C-methyl-ribofuranose **9** from lactone **6** was low. The acetates **11**, **12**, and **14** are key intermediates for the synthesis of 1'-C-methyl-nucleosides. Under standard acetylating conditions the 3,4-*O*-benzylidene derivative **9** gave the acetate mixture **12** in low yields and an open form was the only product obtained from the benzyl derivative **10**. Only the acetate of 3,4-*O*-isopropylidene-1-C-methyl-ribofuranose **11** could be prepared in satisfactory yield.^[12] In light of our results, starting from **1a**, only the synthetic pathway leading to the acetates **11** is suitable for the synthesis of 1'-C-methyl-nucleosides.

EXPERIMENTAL

General

Melting points were recorded on a Stuart Scientific SMP3 instrument and are uncorrected. Optical rotations were measured on a Perkin-Elmer 241 polarimeter using sodium lamp at 589 nm in CHCl₃. ¹H NMR spectra were recorded at 303 K on Bruker AM-500 spectrometer operating at 500.13 and 125.76 MHz for ¹H and ¹³C, respectively, equipped with an Aspect 3000 computer, a process control, and an array processor. The ¹H NMR chemical shifts are reported in parts per million, using as reference the signal for residual solvent protons (7.24 for CDCl₃), and coupling constants (*J*) are given in Hertz. In the ¹³C NMR spectra the residual solvent signal was used as an internal reference (CDCl₃, triplet at $\delta = 77.23$ ppm). All assignments were confirmed with the aid of two-dimensional ¹H,¹H (COSYGPQF) or ¹H,¹³C (INV4GPQF) or ¹H,¹³C (INV4GPLRNDQF) experiments using standard Bruker pulse programs. Mass spectra were recorded on Finnigan LCQ-Deca (Termoquest) in ESI positive-ion mode, KV 5.00, 225°C, 15 V.

The progress of all reactions and column chromatography were monitored by TLC (Silica Gel 60 F₂₅₄ precoated plates with fluorescent indicator, Merck).

Purification of products was achieved by flash chromatography using silica gel 60 (230–400 mesh, Merck). 2,3,5-Tri-*O*-benzyl-D-ribofuranose (**4**),^[20] 6-*O*-(*tert*-butyldimethylsilyl)-3,4-*O*-isopropylidene-1-deoxy-D-psicofuranose (**8**), and 2-*O*-acetyl-6-*O*-(*tert*-butyldimethylsilyl)-3,4-*O*-isopropylidene-1-deoxy-D-psicofuranose (**11**)^[11] were prepared according to literature and verified by NMR and ESI-MS.

2,3-*O*-Benzylidene- α/β -D-ribofuranose (**3a**)

A mixture of D-ribose **1a** (1.0 g, 6.6 mmol), ZnCl₂ (0.83 g, 6.1 mmol), and benzaldehyde (4.5 mL, 45.0 mmol) was stirred for 18 h. Aqueous 40%

NaHSO₃ (75 mL) was added, the mixture stirred for 15 min, and, after evaporation at reduced pressure, the residue was treated with CH₂Cl₂ (120 mL). The resulting slurry was stirred vigorously for 1 h and filtered and the filtrate evaporated. The residue was purified by flash chromatography (petroleum ether/ethyl acetate, 6:4) and two products were separated corresponding to α -anomer (R_f 0.125 in petroleum ether/ethyl acetate, 6:4) and β -anomer (R_f 0.375 in petroleum ether/ethyl acetate, 6:4) (1:8) of the *endo/exo* mixture of title compound (64% yield).^[19]

β -3a: 0.90 g; ¹H NMR *endo* δ = 7.45–7.44 (m, 5H, Ph), 5.80 (s, 1H, *H*-CPh), 5.56 (d, *J* < 1, 1H, *H*-1), 4.90 (d, *J* = 6.2 Hz, 1H, *H*-2), 4.68 (d, *J* = 6.2 Hz, 1H, *H*-3), 4.58–4.57 (m, 1H, *H*-4), 3.82–3.75 (m, AB part of ABX system, 2H, *H*-5a,b) ppm; *exo* δ = 7.39–7.36 (m, 5H, Ph), 5.97 (s, 1H, *H*-CPh), 5.53 (d, *J* < 1, 1H, *H*-1), 4.98 (d, *J* = 5.6 Hz, 1H, *H*-2), 4.69 (d, *J* = 5.6 Hz, 1H, *H*-3), 4.53–4.50 (m, 1H, *H*-4), 3.82–3.75 (m, AB part of ABX system, 2H, *H*-5a,b) ppm.

α -3a: 0.11 g; ¹H NMR *endo* δ = 7.47–7.44 (m, 5H, Ph), 6.0 (s, 1H, *H*-CPh), 5.96 (d, *J* = 3.7, 1H, *H*-1), 4.63 (dd, *J* = 3.7 Hz, *J* = 5.3 Hz, 1H, *H*-2), 4.09 (dd, *J* = 5.3 Hz, *J* = 8.4 Hz, 1H, *H*-3), 3.97 (dd, *J* = 2.7 Hz, *J* = 12.1 Hz, 1H, *H*-5a), 3.91 (ddd, *J* = 2.7 Hz, *J* = 2.7 Hz, *J* = 8.4 Hz, 1H, *H*-4), 3.73 (dd, *J* = 2.7 Hz, *J* = 12.1 Hz, 1H, *H*-5b) ppm; *exo* δ = 7.41–7.38 (m, 5H, Ph), 6.18 (s, 1H, *H*-CPh), 5.98 (d, *J* = 3.7, 1H, *H*-1), 4.71 (dd, *J* = 3.7 Hz, *J* = 5.3 Hz, 1H, *H*-2), 4.11 (dd, *J* = 5.3 Hz, *J* = 8.4 Hz, 1H, *H*-3), 3.97 (dd, *J* = 2.7 Hz, *J* = 12.1 Hz, 1H, *H*-5a), 3.91 (ddd, *J* = 2.7 Hz, *J* = 2.7 Hz, *J* = 8.4 Hz, 1H, *H*-4), 3.73 (dd, *J* = 2.7 Hz, *J* = 12.1 Hz, 1H, *H*-5b) ppm.

5-*O*-(*tert*-Butyldimethylsilyl)-2,3-*O*-benzylidene- α/β -D-ribofuranose (**3b**)

To a solution of the α/β mixture of **3a** (1.0 g, 4.2 mmol) in dry CH₂Cl₂ (50 mL) under N₂, triethylamine (0.64 mL, 4.6 mmol), DMAP (0.05 g, 0.42 mmol) in dry CH₂Cl₂ (5 mL) and *tert*-butyldimethylsilylchloride (0.69 g, 4.6 mmol) in dry CH₂Cl₂ (30 mL) were sequentially added. The mixture was stirred at rt for 5 h and treated with 1M HCl solution to acidic pH, then with NaHCO₃ and H₂O to pH 7.0. The solution was dried on Na₂SO₄ and evaporated under reduced pressure to give crude α/β mixture of **3b** (0.90 g, 83% yield, *endo/exo*).^[24]

β -3b: ¹H NMR *endo* δ = 7.54–7.51 (m, 2H, Ph), 7.43–7.38 (m, 3H, Ph), 5.79 (s, 1H, *H*-CPh), 5.47 (d, *J* < 1, 1H, *H*-1), 4.82 (d, *J* = 5.0 Hz, 1H, *H*-2), 4.64 (d, *J* = 5.0 Hz, 1H, *H*-3), 4.54 (dd, *J* = 2.4 Hz, *J* = 2.4 Hz, 1H, *H*-4), 3.88–3.82 (m, AB part of ABX system, 2H, *H*-5a,b), 0.98 (s, 9H, SiC(CH₃)₃), 0.18 (s, 3H, SiCH₃), 0.16 (s, 3H, SiCH₃) ppm; *exo* δ = 7.50–7.48 (m, 2H, Ph), 7.54–7.51 (m, 2H, Ph), 6.00 (s, 1H, *H*-CPh), 5.44 (d, *J* < 1, 1H, *H*-1), 4.92 (d, *J* = 5.0 Hz, 1H, *H*-2), 4.66 (d, *J* = 5.0 Hz, 1H, *H*-3), 4.49 (dd, *J* = 2.4 Hz,

$J = 2.4$ Hz, 1H, H-4), 3.84–3.78 (m, AB part of ABX system, 2H, H-5a,b) 0.97 (s, 9H, SiC(CH₃)₃), 0.19 (s, 3H, SiCH₃), 0.18 (s, 3H, SiCH₃) ppm.

α -3b: ¹H NMR *endo* $\delta = 7.52$ –7.48 (m, 2H, Ph), 7.43–7.38 (m, 3H, Ph), 6.02 (s, 1H, *H*-CPh), 5.88 (d, $J = 4.6$, 1H, H-1), 4.50 (dd, $J = 4.6$ Hz, $J = 4.8$ Hz, 1H, H-2), 4.25 (dd, $J = 4.8$ Hz, $J = 5.3$ Hz, 1H, H-3), 3.95–3.90 (m, *m* 1H, H-4), 3.76–3.69 (m, AB part of ABX system, 2H, H-5a,b), 0.97 (s, 9H, SiC(CH₃)₃), 0.18 (s, 3H, SiCH₃), 0.16 (s, 3H, SiCH₃) ppm; *exo* $\delta = 7.62$ –7.58 (m, 2H, Ph), 7.43–7.38 (m, 3H, Ph), 6.17 (s, 1H, *H*-CPh), 5.91 (d, $J = 4.6$, 1H, H-1), 4.61 (dd, $J = 4.6$ Hz, $J = 4.8$ Hz, 1H, H-2), 4.23 (dd, $J = 4.8$ Hz, $J = 5.3$ Hz, 1H, H-3), 3.92–3.87 (m, 1H, H-4), 3.72–3.66 (m, AB part of ABX system, 2H, H-5a,b), 0.98 (s, 9H, SiC(CH₃)₃), 0.19 (s, 3H, SiCH₃), 0.15 (s, 3H, SiCH₃) ppm.

General Procedure for the Tetrapropylammonium Perruthenate (TPAP) Oxidation

A solution of ribofuranose derivative (5.0 mmol) in dry CH₂Cl₂ (40 mL) with NMMO (1.17 g, 10.0 mmol) and molecular sieves (2.5 g) was stirred at rt and TPAP (0.175 g, 0.5 mmol) was added. After 30 min of stirring, the oxidation was complete and was filtered on a celite pad that was then washed with CH₂Cl₂. The filtrate was evaporated under reduced pressure to give the crude product.

5-*O*-(*tert*-Butyldimethylsilyl)-2,3-*O*-isopropylidene-*D*-ribo-1,4-lactone (5)

Colorless crystals (1.44 g, 95%); mp 69–71°C [lit.^[25] 69–70°C]; [α]_D²⁰ –48.7 (c = 1.00, CHCl₃) { [¹³C][α]_D²⁰ –46.6 (c = 0.80, CHCl₃)}; ¹H NMR: $\delta = 4.76$ –4.72 (m, 2H, H-2 and H-3), 4.61 (ddd, $J = 1.0$ Hz, $J = 1.9$ Hz, $J = 5.6$ Hz, 1H, H-4), 3.91 (dd, $J = 1.9$ Hz, $J = 11.3$ Hz, 1H, H-5a), 3.82 (dd, $J = 1.0$ Hz, $J = 11.3$ Hz, 1H, H-5b), 1.49 (s, 3H, CH₃), 1.40 (s, 3H, CH₃), 0.89 (s, 3H, SiC(CH₃)₃), 0.09 (s, 3H, SiCH₃), 0.07 (s, 3H, SiCH₃) ppm. ¹³C NMR (500 MHz; CDCl₃, 25°C): $\delta = 174.17$ (C=O), 112.99 (C_{quat}), 82.31 (C-4), 78.47 (C-3), 75.79 (C-2), 62.98 (C-5), 26.78 (CCH₃), 25.76 (SiC(CH₃)₃), 25.58 (CCH₃), 18.19 (SiC(CH₃)₃), –5.62 (SiCH₃), –5.77 (SiCH₃) ppm. *M/z* 320 (M + NH₃)⁺.

5-*O*-(*tert*-Butyldimethylsilyl)-2,3-*O*-benzylidene-*D*-ribo-1,4-lactone (6)

Colorless syrup (1.66 g, 95%, *endo/exo* 3:1).

endo-**6:** ¹H NMR $\delta = 7.49$ –7.47 (2H, m, Ph), 7.43–7.41 (m, 3H, Ph), 5.99 (s, 1H, PhCH), 4.90–4.87 (m, 2H, H-2 and H-3), 4.77–4.76 (ddd, $J < 1.0$ Hz, $J = 1.3$ Hz, $J = 2.0$ Hz 1H, H-4), 3.96 (dd, $J = 2.0$ Hz, $J = 11.3$ Hz, 1H, H-5a), 3.87 (dd, $J = 1.3$ Hz, $J = 11.3$ Hz, 1H, H-5b), 0.93 (s, 9H, SiC(CH₃)₃), 0.12 (s, 3H, SiCH₃), 0.11 (s, 3H, SiCH₃) ppm. ¹³C NMR: $\delta = 172.95$ (C=O), 135.29

(*PhC*), 130.06 (*PhCH*), 128.52 (*PhCH*), 126.85 (*PhCH*), 106.57 (*PhCH*), 81.61 (C-3), 80.08 (C-2), 75.91 (C-4), 63.17 (C-5), 25.79 (SiC(CH₃)₃), 18.22 (SiC(CH₃)₃), -5.58 (SiCH₃), -5.72 (SiCH₃) ppm. *M/z* 373 (M + Na), 723 (M + M + Na).

exo-**6**: ¹H NMR δ = 7.51–7.48 (2H, m, Ph), 7.43–7.42 (m, 3H, Ph), 5.98 (s, 1H, *PhCH*), 4.99 (d, *J* = 5.7 Hz, 1H, H-2), 4.82–4.80 (m, 2H, H-3 and H-4), 3.94 (dd, *J* = 2.0 Hz, *J* = 11.4 Hz, 1H, H-5a), 3.87 (dd, *J* = 1.2 Hz, *J* = 11.4 Hz, 1H, H-5b), 0.91 (s, 9H, SiC(CH₃)₃), 0.11 (s, 3H, SiCH₃), 0.10 (s, 3H, SiCH₃) ppm. ¹³C NMR: δ = 173.05 (C=O), 135.70 (*PhC*), 130.05 (*PhCH*), 128.49 (*PhCH*), 126.47 (*PhCH*), 104.60 (*PhCH*), 84.13 (C-3), 77.86 (C-2), 76.42 (C-4), 63.18 (C-5), 25.77 (SiC(CH₃)₃), 18.21 (SiC(CH₃)₃), -5.62 (SiCH₃), -5.72 (SiCH₃) ppm. *M/z* 373 (M + Na), 723 (M + M + Na).

2,3,5-*O*-Tribenzyl-*D*-ribo-1,4-lactone (**7**)

Colorless crystals (1.98 g, 95%); mp 53–54°C [lit.^[26] 54–55°C]; [α]_D²⁰ +73.6 (*c* = 1.00, CHCl₃) {lit.^[27] [α]_D²⁰ +74.1 (*c* = 2.00, CHCl₃)}; ¹H NMR: δ = 7.45–7.30 (m, 13H, Ph), 7.24–7.17 (m, 2H, Ph), 4.98 (d, *J* = 11.9 Hz, 1H, *CHHPh*), 4.78 (d, *J* = 11.9 Hz, 1H, *CHHPh*), 4.73 (d, *J* = 11.9 Hz, 1H, *CHHPh*), 4.60 (d, *J* = 11.9 Hz, 1H, *CHHPh*), 4.57 (ddd, *J* = 1.6 Hz, *J* = 2.4 Hz, *J* = 2.7 Hz, 1H, H-4), 4.52 (d, *J* = 11.0 Hz, 1H, *CHHPh*), 4.45 (d, *J* = 5.9 Hz, 1H, H-2), 4.44 (d, *J* = 11.0 Hz, 1H, *CHHPh*), 4.14 (dd, *J* = 5.9 Hz, *J* = 1.6 Hz, 1H, H-3), 3.69 (dd, *J* = 2.7 Hz, *J* = 11.0 Hz, 1H, H-5a), 3.59 (dd, *J* = 2.4 Hz, *J* = 11.0 Hz, 1H, H-5b) ppm. ¹³C NMR: δ = 173.74 (C=O), 137.30 (*PhCH*₂), 137.19 (*PhCH*₂), 173.01 (*PhCH*₂), 128.54 (*PhCH*₂), 128.28 (*PhCH*₂), 128.14 (*PhCH*₂), 128.08 (*PhCH*₂), 128.02 (*PhCH*₂), 127.63 (*PhCH*₂), 81.82 (C-4), 75.43 (C-3), 73.78 (CH₂), 73.68 (C-2), 72.76 (CH₂), 72.42 (CH₂), 68.80 (C-5) ppm. *M/z* 441 (M + Na).

General Procedure for the Methylation of *D*-Ribonolactone Derivatives

To a stirred solution of 1.6 M methyllithium in diethyl ether (2.13 mL) at -70°C under argon atmosphere, a solution of *D*-ribonolactone derivative (2.0 mmol) in anhydrous diethyl ether (20 mL) was added dropwise. After 1 h the mixture was warmed to 0°C, treated with 10% aqueous NH₄Cl (20 mL) and extracted with diethyl ether (3 × 20 mL). The combined organic solutions were washed with ice-cold water (2 × 15 mL) and dried over anhydrous Na₂SO₄. Removal of the solvent under reduced pressure and purification of the residue by flash chromatography (petroleum ether/ethyl acetate, 9:1) afforded required 1-deoxy-psicofuranoside.

6-O-(tert-Butyldimethylsilyl)-3,4-O-benzylidene-1-deoxy-D-psicofuranose (9)

Colorless syrup (0.28 g, 38%, 3:1 *endo/exo*).

endo-**9**: $^1\text{H NMR } \delta = 7.53\text{--}7.50$ (m, 2H, Ph), 7.43–7.40 (m, 3H, Ph), 5.94 (s, 1H, PhCH), 4.76 (d, 1H, $J = 5.1$ Hz, H-3), 4.25 (dd, $J = 5.1$ Hz, $J = 7.1$ Hz, 1H, H-4), 3.85 (dd, $J = 6.0$ Hz, $J = 6.0$ Hz, 1H, H-6a), 3.79–3.75 (m, 2H, H-5 and H-6b), 2.38 (s, 3H, CH₃), 0.93 (s, 9H, SiC(CH₃)₃), 0.11 (s, 3H, SiCH₃), 0.10 (s, 3H, SiCH₃) ppm.

exo-**9**: $^1\text{H NMR } \delta = 7.52\text{--}7.49$ (m, 2H, Ph), 7.44–7.40 (m, 3H, Ph), 5.92 (s, 1H, PhCH), 5.05 (dd, 1H, $J = 1.3$ Hz, $J = 5.1$ Hz, H-4), 4.57 (d, $J = 5.1$ Hz, 1H, H-3), 4.41 (ddd, $J = 1.3$ Hz, $J = 1.9$ Hz, $J = 1.9$ Hz, 1H, H-5), 3.90–3.80 (m, 2H, H-6a and H-6b), 1.62 (s, 3H, CH₃), 0.97 (s, 9H, SiC(CH₃)₃), 0.19 (s, 3H, SiCH₃), 0.18 (s, 3H, SiCH₃) ppm.

3,4,6-Tribenzyl-1-deoxy-D-psicofuranose (10)

Colorless syrup (0.79 g, 91%, anomeric mixture 1: 3.5 ratio);^[28] major isomer: $^1\text{H NMR } \delta = 7.43\text{--}7.35$ (m, 15H, Ph), 4.73 (d, $J = 11.5$ Hz, 1H, CHHPh), 4.62 (d, $J = 11.5$ Hz, 1H, CHHPh), 4.67–4.61 (AB system, 2H, CH₂Ph), 4.57 (d, $J = 12.0$ Hz, 1H, CHHPh), 4.52 (d, $J = 12.0$ Hz, 1H, CHHPh), 4.35 (ddd, $J = 2.2$ Hz, $J = 3.5$ Hz, $J = 4.8$ Hz, 1H, H-5), 4.04 (dd, $J = 2.2$ Hz, $J = 5.1$ Hz, 1H, H-4), 3.76 (d, $J = 5.1$ Hz, 1H, H-3), 3.54 (dd, $J = 3.5$ Hz, $J = 10.4$ Hz, 1H, H-6a), 3.48 (dd, $J = 4.8$ Hz, $J = 10.4$ Hz, 1H, H-6b), 1.51 (s, 1H, CH₃) ppm. minor isomer: $^1\text{H NMR } \delta = 7.34\text{--}7.27$ (m, 15H, Ph), 4.80 (d, $J = 11.8$ Hz, 1H, CHHPh), 4.75 (d, $J = 11.8$ Hz, 1H, CHHPh), 4.58 (d, $J = 11.0$ Hz, 1H, CHHPh), 4.50 (d, $J = 11.0$ Hz, 1H, CHHPh), 4.46–4.40 (AB system, 2H, CH₂Ph), 4.31–4.29 (m, 1H, H-5), 4.01 (dd, $J = 2.4$ Hz, $J = 4.4$ Hz, 1H, H-4), 3.84 (d, $J = 4.4$ Hz, 1H, H-3), 3.68 (dd, $J = 2.6$ Hz, $J = 10.4$ Hz, 1H, H-6a), 3.65 (dd, $J = 3.0$ Hz, $J = 10.4$ Hz, 1H, H-6b), 1.58 (s, 1H, CH₃) ppm.

General Procedure for the Acetylation of 1-Deoxy-D-psicofuranoses

To a solution of 1-deoxy-psicofuranose (1.0 mmol) and DMAP (5 mg, 0.04 mmol) in pyridine (2 mL), acetic anhydride (0.11 mL, 1.0 mmol) was added dropwise and the reaction was stirred at rt for 5 h. Ice-cold water (5 mL) was then added and the aqueous phase was extracted with CHCl₃ (3 × 3 mL). The combined organic layers were washed with a cold saturated NaHCO₃ solution (3 × 3 mL), dried over anhydrous Na₂SO₄, and evaporated under reduced pressure.

5-O-Acetyl-3,4,6-tri-O-benzyl-1-deoxy-D-psicose (13)

From 3,4,6-tribenzyl-1-deoxy-D-psicofuranose (**10**), compound **13** was purified by flash chromatography (petroleum ether/ethyl acetate, 8:2);

colorless syrup (0.29 g, 60%); $[\alpha]_{\text{D}}^{20} + 0.0$ ($c = 1.00$, CHCl_3); $^1\text{H NMR}$ $\delta = 7.36$ – 7.24 (m, 15H, Ph), 5.32 (ddd, $J = 4.0$ Hz, $J = 4.0$ Hz, $J = 6.8$ Hz, 1H, H-5), 4.65 (d, $J = 11.9$ Hz, 1H, CHHPh), 4.62–4.59 (AB system, 2H, CH_2Ph), 4.60 (d, $J = 11.9$ Hz, 1H, CHHPh), 4.56 (d, $J = 12.0$ Hz, 1H, CHHPh), 4.48 (d, $J = 12.0$ Hz, 1H, CHHPh), 4.21 (dd, $J = 4.0$ Hz, $J = 6.8$ Hz, 1H, H-4), 4.05 (d, $J = 4.0$ Hz, 1H, H-3), 3.78–3.72 (m, 2H, H-6a,b), 2.14 (s, 3H, COCH_3), 2.05 (s, 3H, OCOCH_3) ppm. $^{13}\text{C NMR}$: $\delta = 208.19$ (C=O), 169.76 (C=O), 138.03 (PhC), 137.44 (PhC), 137.26 (PhC), 128.48 (PhCH), 128.42 (PhCH), 128.07 (PhCH), 127.99 (PhCH), 127.90 (PhCH), 127.74 (PhCH), 127.69 (PhCH), 83.41 (C-3), 78.43 (C-4), 73.25 (CH_2), 73.17 (CH_2), 72.92 (CH_2), 71.35 (C-5), 68.14 (C-6), 27.15 (OCOCH_3), 21.15 (1-CH_3) ppm. M/z 499 (M + Na).

Anal. Calcd for $\text{C}_{29}\text{H}_{32}\text{O}_6$: C, 73.09; H, 6.67. Found: C, 73.22; H, 6.74.

ACKNOWLEDGMENTS

This work has been financially supported by Università degli Studi di Milano (Fondi FIRST).

REFERENCES

- [1] Bonate, P.L.; Arthaud, L.; Cantrell, W.R., Jr.; Stephenson, K.; Secrist III, J.A.; Weitman, S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. *Nat. Rev. Drug Discov.* **2006**, *5*, 855–863.
- [2] De Clercq, E. Recent highlights in the development of new antiviral drugs. *Curr. Opin. Microbiol.* **2005**, *8*, 552–560.
- [3] Macchi, B.; Mastino, A. Pharmacological and biological aspects of basic research on nucleoside-based reverse transcriptase inhibitors. *Pharmacol. Res.* **2002**, *46*, 473–482.
- [4] Ren, J.; Stammers, D.K. HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance. *Trend. Pharm. Sci.* **2005**, *26*, 4–7.
- [5] Bloch, A.; Robins, M.J.; McCarthy, J.R., Jr. The role of the 5'-hydroxyl group of adenosine in determining substrate specificity for adenosine deaminase. *J. Med. Chem.* **1967**, *10*, 908–912.
- [6] Faivre-Buet, V.; Grouiller, A.; Descotes, G. Synthesis of thymine nucleosides derived from 1-deoxy-D-psicofuranose. *Nucleos. Nucleot. Nucl.* **1992**, *11*, 1651–1660.
- [7] Hayakawa, H.; Miyazawa, M.; Tanaka, H.; Miyasaka, T. A ribonolactone-based approach to the synthesis of 1'-carbon-substituted thymine ribonucleosides. *Nucleos. Nucleot. Nucl.* **1994**, *13*, 297–308.
- [8] Kodama, T.; Shuto, S.; Nomura, M.; Matsuda, A. An efficient method for the preparation of 1'-alpha-branched-chain sugar pyrimidine ribonucleosides from uridine: the first conversion of a natural nucleoside into 1'-substituted ribonucleosides. *Chem. Eur. J.* **2001**, *7*, 2332–2340.

- [9] Cappellacci, L.; Barboni, G.; Palmieri, M.; Pasqualini, M.; Grifantini, M.; Costa, B.; Martini, C.; Franchetti, P. Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues. *J. Med. Chem.* **2002**, *45*, 1196–1202.
- [10] Sommadossi, J.-P.; Gosselin, G.; Storer, R.; Egan, J. PCT Int. Appl. 2006, Application: WO 2005-US34786 20050926. Priority: US 2004–613085 20040924.
- [11] Ciuffreda, P.; Buzzi, B.; Alessandrini, L.; Santaniello, E. Activity of adenosine deaminase (ADA) and adenylyl deaminase (AMPDA) towards 6-chloropurine nucleosides modified in the ribose moiety. *Eur. J. Org. Chem.* **2004**, 4405–4409.
- [12] Ciuffreda, P.; Alessandrini, L.; Santaniello, E. 2',3'-Isopropylidene group, a molecular scaffold to study the activity of adenosine and adenylyl deaminase on adenosine analogues modified in the ribose moiety. *Nucleos. Nucleot. Nucl.* **2007**, *26*, 1311–1313.
- [13] Kaskar, B.; Heise, G.L.; Michalak, R.S.; Vishnuvajjala, B.R. A convenient large scale synthesis of protected D-ribonolactone from D-ribose. *Synthesis* **1990**, 1031–1032.
- [14] Batra, H.; Moriarty, R.M.; Penmasta, R.; Sharma, V.; Stanciuc, G.; Staszewski, J.P.; Tuladhar, S.M.; Walsh, D.A. A concise, efficient and production-scale synthesis of a protected L-lyxonolactone derivative: an important aldonolactone core. *Org. Process Res. Dev.* **2006**, *10*, 484–486.
- [15] Liu, D.; Caperelli, C.A. A new synthesis of D-ribonolactone from D-ribose by pyridinium chlorochromate oxidation. *Synthesis* **1991**, 933–934.
- [16] Ley, S.V.; Norman, J.; Griffith, W.P.; Marsden, S.P. Tetrapropylammonium per-ruthenate, $\text{Pr}_4\text{N}^+\text{RuO}_4^-$, TPAP: a catalytic oxidant for organic synthesis. *Synthesis* **1994**, 639–666.
- [17] Benhaddou, R.; Czernecki, S.; Farid, W.; Ville, G.; Xie, J.; Zegar, A. Tetra-n-propylammonium tetra-oxoruthenate(VII): a reagent of choice for the oxidation of diversely protected glycopyranoses and glycofuranoses to lactones. *Carbohydr. Res.* **1994**, *260*, 243–250.
- [18] Wood, H.B.; Diehl, H.W.; Fletcher, H.G. Some products arising from the condensation of D-ribose with benzaldehyde. 2,3-O-benzylidene- β -D-ribofuranose and di-(2,3-O-benzylidene-D-ribofuranose)-1,5':1',5-dianhydride. *J. Am. Chem. Soc.* **1956**, *78*, 4715–4717.
- [19] Grindley, T.B.; Szarek, W.A. Configurational and conformational studies on some benzylidene derivatives of D-ribose and di- β -D-ribofuranose 1-5':1',5-dianhydride. *Carbohydrate Res.* **1972**, *25*, 187–195.
- [20] Barker, R.; Fletcher, H.G. 2,3,5-tri-O-benzyl-D-ribosyl and L-arabinosyl bromides. *J. Org. Chem.* **1961**, *26*, 4605–4609.
- [21] Wu, Q.; Simons, C. Synthetic methodologies for C-nucleosides. *Synthesis* **2004**, 1533–1553.
- [22] Cavicchioli, S.; Savoia, D.; Trombini, C.; Umami-Ronchi, A. Syntheses of hydroxy ketones from lactones. *J. Org. Chem.* **1984**, *49*, 1246–1251.
- [23] Rodriguez, J.B. Chiral 1,4-dicarbonyl-2,3-O-isopropylidene derivatives. Rapid racemization on standing. *Tetrahedron* **1999**, *55*, 2157–2170.
- [24] Grochowski, E.; Stepowska, H. The synthesis of "C-O-N" analogues of nucleosides via the Mitsunobu reaction. *Synthesis* **1988**, 795–797.
- [25] Cheng, J.C.-Y.; Hacksell, U.; Daves, G.D., Jr. Differentially Protected ribofuranoid glycals. *J. Org. Chem.* **1985**, *50*, 2778–2780.

- [26] Timpe, W.; Dax, K.; Wolf, N.; Weidemann, H. 3-desoxyhex-2-enono-1,4-lactone aus D-hexofuran(osid)-urono-6,3-lactonen. *Carbohydrate Res.* **1975**, *39*, 53–60.
- [27] Jensen, H.S.; Limberg, G.; Pedersen, C. Benzylolation of aldonolactones with benzyl trichloroacetimidate. *Carbohydrate Res.* **1997**, *302*, 109–112.
- [28] Sharma, G.V.M.; Chander, A.S.; Krishnudu, K.; Krishna, R.P. A simple and efficient PdCl₂ mediated conversion of γ , δ , -olefinic alcohols into C-glycosides. *Tetrahedron Lett.* **1997**, *38*, 9051–9054.